Table 2 |
|||||
|
Analyses of variance |
|||||
| Absolute Count |
Percent CD4+ or CD8+ T cells |
||||
|
|
|||||
| Subjects |
Population |
pp65+IE-1 stimulation, HIV- vs HIV+ subjects |
pp65+IE-1 vs Gag+Env stimulation, HIV+ subjects |
pp65+IE-1 stimulation, HIV- vs HIV+ subjects |
pp65+IE-1 vs Gag+Env stimulation, HIV+ subjects |
|
|
|||||
| All |
(CD4+ IFNγ+) |
<.000011 |
0.00120 |
0.08193 |
0.11850 |
| (CD4+ IFNγ+ IL-2+) |
<.00001 |
0.00310 |
0.99855 |
0.01903 |
|
| (CD8+ IFNγ+) |
0.00001 |
0.00002 |
0.05149 |
<.00001 |
|
| (CD8+ IFNγ+ IL-2+) |
0.82219 |
0.06415 |
0.80507 |
0.00760 |
|
| Non-ART only |
(CD4+ IFNγ+) |
<.00001 |
0.00016 |
0.05508 |
0.01023 |
| (CD4+ IFNγ+ IL-2+) |
<.00001 |
0.00184 |
0.98033 |
0.02026 |
|
| (CD8+ IFNγ+) |
0.99841 |
0.00001 |
0.94575 |
0.00008 |
|
| (CD8+ IFNγ+ IL-2+) |
0.18590 |
0.09745 |
0.57196 |
0.05185 |
|
|
1 All results are expressed as p-values. p < 0.05 was considered significant (shown in bold). | |||||
Nomura et al. AIDS Research and Therapy 2006 3:18 doi:10.1186/1742-6405-3-18 |
|||||
